Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity.

ABSTRACT: Five-year survival for childhood cancer now exceeds 85%. However, for many patients, treatment requires the use of intensive anthracycline-based chemotherapy and radiotherapy, both of which are associated with significant long-term cardiovascular toxicity. As such, late cardiovascular disease is now one of the leading causes of premature morbidity and mortality among childhood cancer survivors. Recent advances over the past decade have refined the cardiotoxic potential of various chemotherapeutics, and ongoing work seeks to determine the efficacy of various cardioprotective strategies in children receiving active cancer therapy. The development of risk prediction models offers an additional strategy to define risk for both newly treated and long-term survivors. Current screening strategies

SUBMITTER: Bottinor W 

PROVIDER: S-EPMC9820865 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature